Skip to main content
    G

    Grace Therapeutics, Inc. (GRCE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.75
    -0.06 (-3.31%)

    Market Cap: $38.08M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Grace Therapeutics, Inc. (GRCE) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Grace Therapeutics reported revenue of $0 for the fiscal year ended Mar 31, 2026. That year, net income was -$7.79M, operating cash flow was -$8.87M and free cash flow was -$8.87M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$2.13M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Mar 2026, with an operating loss of $11.08M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Mar 2026$0N/AN/AN/AN/A
    Mar 2025$0N/AN/AN/AN/A
    Mar 2024$0N/AN/AN/AN/A
    Mar 2023$0N/AN/AN/AN/A
    Mar 2022$0-100.0%N/AN/AN/A
    Mar 2021$309.32KN/A61.2%-8377.1%-10039.8%
    Mar 2020N/AN/AN/AN/AN/A
    Mar 2019N/AN/AN/AN/AN/A
    Mar 2018N/AN/AN/AN/AN/A
    Mar 2017N/AN/AN/AN/AN/A
    Annual, fiscal years ended Mar 2017 to Mar 2026

    Income Statement

    In the fiscal year ended Mar 2026, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Revenue$0$0$0$0$0$309.32KN/AN/AN/AN/A
    Cost of revenue$7.00K$7.00K$11.00K$124.00K$0$119.94KN/A$3.12M$2.68M$2.57M
    Gross profit-$7.00K-$7.00K-$11.00K-$124.00K$0$189.38KN/AN/A-$2.68M-$2.57M
    Research and development$2.40M$13.54M$6.35M$13.49M$6.95M$6.59M$31.92M$29.37M$12.13M$7.18M
    Operating income-$11.08M-$23.75M-$17.44M-$70.54M-$19.48M-$25.91M-$48.83M-$34.41M-$15.25M-$10.52M
    Net income-$7.79M-$13.63M-$17.44M-$57.39M-$12.27M-$31.05M-$50.98M-$39.37M-$16.65M-$10.56M
    EBITDA-$11.07M-$23.75M-$15.41M-$24.56M-$19.17M-$15.68M-$47.40MN/A-$14.30M-$7.95M
    Fiscal years ended Mar 2017 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$8.00K$0$0$0$0$0
    Gross profitN/AN/A-$2.00K-$4.12K-$2.00K-$2.00K-$2.00K-$2.00K-$2.00K-$1.00K-$1.00K-$1.00K
    Operating income-$2.29M-$15.79M-$3.01M-$3.36M-$3.53M-$3.09M-$4.53M-$5.33M-$4.83M-$6.79M-$4.43M-$4.03M
    Net income-$2.13M-$15.79M-$1.18M-$3.18M-$1.31M-$3.36M$905.73K-$5.98M-$3.43M-$3.58M-$4.30M-$3.17M
    Last 12 quarters

    Balance Sheet

    As of Mar 2026, cash and equivalents of $16.98M were 25.5% of total assets of $66.65M, against total liabilities of $2.76M.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Total assets$66.65M$71.99M$73.30M$79.12M$128.62M$78.46M$32.30M$36.90M$17.78M$25.48M
    Current assets$17.38M$22.71M$24.01M$29.29M$45.53M$78.35M$22.56M$27.97M$7.35M$10.20M
    Cash and equivalents$16.98M$22.13M$23.00M$27.88M$30.34M$64.00M$20.13M$16.87M$6.37MN/A
    Total liabilities$2.76M$5.38M$11.56M$11.17M$20.35M$8.54M$13.94M$25.85M$11.41M$3.76M
    Short-term debtN/AN/AN/A$75.00K$104.00K$108.04K$229.00K$1.36MN/AN/A
    Shareholder equity$63.90M$66.61M$61.74M$67.95M$108.27M$69.92M$18.37M$11.04M$6.37M$21.72M
    Fiscal years ended Mar 2017 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$57.70M$50.07M$66.65M$68.49M$66.58M$69.81M$71.99M$61.22M$65.35M$69.72M$73.30M$76.19M
    Total liabilities$2.22M$1.86M$2.76M$3.60M$3.76M$6.25M$5.38M$9.09M$9.21M$10.35M$11.56M$11.51M
    Cash and equivalents$21.31M$13.76M$16.98M$18.67M$16.86M$20.00M$22.13M$11.05M$15.15M$19.39M$23.00M$18.55M
    Shareholder equity$55.48M$48.21M$63.90M$64.89M$62.82M$63.55M$66.61M$52.14M$56.13M$59.36M$61.74M$64.68M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Mar 2026.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Operating cash flow-$8.87M-$14.90M-$12.33M-$15.91M-$17.23M-$17.99M-$32.44M-$24.79M-$9.69M-$6.94M
    Capital expenditures$0$0$22.00K$17.00K$0$86.68K$450.93K$534.00K$352.33K$2.57M
    Free cash flow-$8.87M-$14.90M-$12.36M-$15.93M-$17.23M-$18.07M-$32.89M-$25.32M-$10.05M-$9.51M
    Investing cash flowN/AN/A$104.00K$13.15M-$3.52M-$12.38M$11.50M-$9.44M-$318.26K$6.85M
    Financing cash flow$3.71M$14.03M$7.36M$304.00K$0$74.73M$18.64M$45.69M$8.83M$7.00M
    Fiscal years ended Mar 2017 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$1.78M-$3.22M-$1.71M-$2.22M-$3.15M-$1.80M-$2.95M-$4.12M-$4.24M-$3.60M-$2.09M-$1.89M
    Capital expenditures$0$0$0$0N/A$0$0N/AN/A$0$22.00K$0
    Free cash flow-$1.78M-$3.22M-$1.71M-$2.22MN/A-$1.80M-$2.95MN/AN/A-$3.60M-$2.11M-$1.89M
    Last 12 quarters

    Frequently Asked Questions About GRCE

    What is Grace Therapeutics' annual revenue?

    Grace Therapeutics reported revenue of $0 for the fiscal year ended Mar 31, 2026.

    Is Grace Therapeutics profitable?

    No. Grace Therapeutics reported net income of -$7.79M for the fiscal year ended Mar 31, 2026.

    How much free cash flow does GRCE generate?

    For the fiscal year ended Mar 31, 2026, operating cash flow of -$8.87M minus capital expenditures of $0 produced free cash flow of -$8.87M.

    How much debt does Grace Therapeutics have?

    The balance sheet dated Mar 31, 2026 reported cash and equivalents of $16.98M.